secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001171843-25-002954
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava reports Q1 net loss of $23.4M, discontinues Alzheimer's program, pivots to TSC epilepsy
--------------------------------------------------------------------------------

- Net loss of $23.4M vs net income of $25.0M in Q1 2024; cash and equivalents $117.3M, no debt.
- R&D expenses $13.7M (down 16% YoY); G&A $10.9M including $3.0M legal accrual, no insurance recoveries.
- Workforce reduced by 10 employees (~33%) in Q1; Alzheimer's program with simufilam to be fully discontinued by end of Q2 2025.
- New license from Yale for TSC-related epilepsy; plans to initiate first clinical study in H1 2026.
- Appointed Dr. Bordey as SVP Neuroscience and Dr. Moore as SVP Clinical Development; CMO Kupiec retiring May 9.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325002954/0001171843-25-002954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325002954/f8k_050825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-002954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer